Innocan Pharma announces that Ramot has filed an international patent application with Tel Aviv University for its unique platform for the distribution of cannabinoid-laden exosomes (CLX)
Herzliya, Israel and Calgary, Alberta – (Newsfile Corp. – September 24, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INPF) (the “Society” Where “Innocan“), hereby announces the filing by Ramot of a new patent application for a unique cannabinoid exosome delivery platform – CLX, developed by Ramot and their researchers at Tel Aviv University. InnoCan owns a worldwide exclusive option agreement to develop and commercialize the CLX and noted Ramot on the intention to execute the option in a full license agreement. The new patent application covers the capacity and applications of a charged exosome with cannabinoids, allowing its precise delivery to target organs This new technique may allow a better drug targeting different indications effectively.
Exosomes have become promising nanocarriers for drug delivery and targeted therapy. Exosomes can act as “guided missiles” targeting specific damaged organs and play an important role in cell-to-cell communication. Exosomes can be loaded with therapeutic ingredients to enhance their potential.
The CLX (Cannabinoid Loaded Exosome) may have the potential to provide a highly synergistic tissue effect such as regeneration and anti-inflammatory properties targeting, among other potential indications, recovery of infected lung cells and central nervous system disease. (SNC).
Figure 1: Professor Dani Offen, from TAU, Iris Bincoch, CEO of InnoCan
To view an improved version of Figure 1, please visit:
Tel Aviv University Professor Offen said that “the ability to load a cannabinoid into an exosome is not insignificant and presents major challenges, which we have now overcome. The ability of such a loading technique may open the door to treating a wide range of different indications where the exosome and cannabinoids each have therapeutic potential separately and together given their synergistic effect. “
“Innocan Pharma continues to lead the advanced development of delivery platforms that will shape the booming cannabinoid-integrated pharmaceutical market,” said CEO Iris Binkovich. “Our exceptionally diverse team combined with unique research capabilities lead InnoCan to the forefront of the cannabinoid-pharmaceutical industry.”
Innocan’s relationship with Tel Aviv University
Innocan Pharma Ltd., a wholly owned subsidiary of the Company, has notified Ramot of Tel Aviv University, the technology transfer company of Tel Aviv University, of its choice to exercise its option to enter into a worldwide exclusive license and research agreement for exosome-laden CBD (or other cannabinoids), in accordance with the license conditions already agreed upon and set out in the option agreement that was signed on April 17e 2020. The research and development initiative is led by Professor Daniel Offen, head of the Tel Aviv University Neurology Laboratory in the Department of Human Genetics and Biochemistry. Professor Daniel Offen has published over 150 original scientific papers on neurodegenerative diseases and is the co-inventor of over a dozen patents. He is co-founder of several biotechnology companies developing gene and cell therapies for neurological disorders.
Ramot is excited about the successful collaboration with Innocan and believes that the new patents and their enormous potential will lead to further breakthroughs in the field of loading and delivery of therapeutic drugs, said Keren Primor Cohen, CEO of Ramot.
Innocan Pharma is a pharmaceutical technology company focused on the development of multiple drug delivery platforms containing CBD. Innocan Pharma and Ramot from Tel Aviv University are collaborating on a revolutionary new exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 coronavirus using CBD. CBD-laden exosomes have the potential to aid in the recovery of infected lung cells. This product, which should be administered by inhalation, will be tested against various lung infections.
Innocan Pharma has signed an exclusive worldwide license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a unique controlled-release liposome-based CBD drug delivery platform for injection. Innocan Israel plans, in collaboration with Prof. Berenholz, to test the liposome platform under several potential conditions. Innocan Israel is also working on a skin product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of pharmaceutical products integrated with CBD, including, but not limited to, topical treatments for symptom relief. psoriasis as well as the treatment of muscle pain and rheumatic pain. The founders and executives of Innocan Israel each have successful business backgrounds in the pharmaceutical and technology sectors in Israel and around the world.
For more information, please contact:
For Innocan Pharma Corporation:
Iris Binkovich, CEO
Lytham Partners, LLC
Ben Shamsian CPA | Vice president
Direct: 646-829-9701; Cell: 516-652-9004`Shamsian
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.
Caution regarding forward-looking information
Certain information contained in this press release, including, without limitation, information regarding research and development, collaborations, the potential to treat conditions and other therapeutic effects resulting from research activities and / or of the Company’s products, required regulatory approvals and timing of market entry, is forward-looking information within the meaning of applicable securities laws. By their nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions regarding the anticipated benefits of the products, the satisfaction of regulatory requirements in various jurisdictions and the satisfactory completion of production and distribution required. .
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from anticipated results or expectations expressed in this press release. Principal risks and uncertainties include, but are not limited to: general economic, market and business conditions, global and local (national); government and regulatory requirements and actions of government authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks inherent in the nature of product distribution, including import / export issues and failure to obtain required regulatory and other approvals (or to do so in a timely manner) and availability on each site. input and finished product market. some products. The expected timeframe for market entry may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for more time to enter into and / or meet manufacturing and service agreements. distribution. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this press release regarding the timing of the commencement of distribution of the product. A full discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from forward-looking information. Innocan does not undertake to update, correct or revise forward-looking information as a result of new information, future events or otherwise, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97538.